Bifunctional Duocarmycin Analogues as Inhibitors of Protein Tyrosine Kinases

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Bifunctional duocarmycin analogues are potent cytotoxic agents.
• They are known inhibitors of aldehyde dehydrogenase 1 (ALDH1).
• Sensitivity in ALDH1-low cells suggests additional targets.

Purpose of the Study:

• To identify novel targets of bifunctional duocarmycin analogues.
• To develop optimized analogues targeting specific cancer pathways.
• To evaluate cytotoxicity against cancer cells with specific biomarker expression.

Main Methods:

• In silico analyses: PCA, structure-similarity search, docking.
• In vitro biochemical validation.
• Chemical synthesis and structural optimization.
• In vitro cytotoxicity assays.

Main Results:

• In silico methods predicted vascular endothelial growth factor receptor 2 (VEGFR-2) as a key target.
• Optimized analogues demonstrated potent VEGFR-2 inhibition.
• Low residual aldehyde dehydrogenase 1 activity was observed.
• High cytotoxicity was confirmed in cancer cells overexpressing ALDH1 and VEGFR-2.

Conclusions:

• Bifunctional duocarmycin analogues represent a new class of cytotoxic compounds.
• Targeting VEGFR-2 offers a promising therapeutic avenue.
• These compounds are effective against cancers with dual ALDH1 and VEGFR-2 overexpression.